A Study to Compare Different Antibiotics and Different Modes of Fluid Treatment for Children With Severe Pneumonia
Model scores of the 29,894 trials active now.
Model score 10% for any early termination, 4% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 10% of the time (313 trials).
Finished trial that started in 2015 or later: the model never saw it during training.
How it ended
Completed on 2024-04-05, after 2019-08-19 start.
The score above never used this outcome: finished trial that started in 2015 or later: the model never saw it during training.
Termination over time, as the model saw it at the start
Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2024-04-05. The rest of the way to 100% is still running.
From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.
What moved the score
-
Wording of the registration (title, summary, criteria) (raises risk) · Wording
Phrases that raised it: treatingconcurrentcareeffectiveline
Phrases that lowered it: 90with severeagedpulsethe study -
Design: factorial (lowers risk) · Design
-
Accepts healthy volunteers: No (raises risk) · Who can join
-
Sponsor's past termination rate: 5.8% (lowers risk) · Sponsor's track record
-
Collaborators: 7 (lowers risk) · Design
-
Phase: 3 (lowers risk) · Design
-
Minimum age: 0.17 (lowers risk) · Who can join
-
Trials the sponsor started in the prior 2 years: 72 (lowers risk) · Sponsor's track record
-
Drug's FAERS reports with a death: 14.4% (lowers risk) · Drug's FDA history
-
Sponsor type: academic or other (raises risk) · Sponsor's track record
-
Number of arms: 6 (lowers risk) · Design
-
Disease area, cancer: No (lowers risk) · Disease area
-
Has a data monitoring committee: Yes (raises risk) · Design
-
Sponsor's past trials: 240 (lowers risk) · Sponsor's track record
-
Primary purpose: treatment (raises risk) · Design
-
Responsible party: principal investigator (lowers risk) · Design
-
Drug's FAERS reports marked serious: 87.7% (raises risk) · Drug's FDA history
Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.
The trial
Design
- Phase
- 3 (typical: 2)
- Number of arms
- 6 (typical: 2)
- Allocation
- randomized
- Design
- factorial (typical: parallel)
- Primary purpose
- treatment
- Blinding
- none
- Has a data monitoring committee
- Yes (typical: 56% yes)
- Responsible party
- principal investigator (typical: sponsor)
- Collaborators
- 7 (typical: 0)
- Keywords listed
- 7 (typical: 1)
Who can join
- Minimum age
- 0.17 (typical: 18)
- Maximum age
- 4.92 (typical: 71)
- Sex
- all
- Accepts healthy volunteers
- No (typical: 9% yes)
Sponsor's track record
- Sponsor type
- academic or other
- Sponsor's past trials
- 240 (typical: 32)
- Sponsor's past termination rate
- 5.8% (typical: 9.9%)
- Trials the sponsor started in the prior 2 years
- 72 (typical: 19)
Drug's FDA history
- Drugs with FDA adverse-event history
- 8 (typical: 1)
- Drug has FAERS history
- Yes (typical: 64% yes)
- Drug's FAERS reports before start
- 58528 (typical: 2148)
- Drug's FAERS reports in the prior 12 months
- 11979 (typical: 412.5)
- Drug's FAERS reports marked serious
- 87.7% (typical: 85.6%)
- Drug's FAERS reports with a death
- 14.4% (typical: 15.9%)
Disease area and drugs
- Disease areas
- infectious disease, respiratory
- Drugs matched to FDA substances
- amoxicillin clavulanate, amoxicillin clavulanic acid, ampicillin, ceftriaxone, gentamicin, penicillin, penicillin g, ringer s
Typical values are among the trials active now. Sponsor and drug history are counted only up to this trial's start date.
Similar finished trials
- Amoxicillin Versus Benzyl Penicillin for Treatment of Children Hospitalised With Severe Pneumonia NCT01399723 · started 2011 · scored riskier than 24% of active trials completed
- Simplified Antibiotic Therapy for Sepsis in Young Infants NCT01027429 · started 2009 · scored riskier than 12% of active trials completed
- Antibiotics for Children With Severe Diarrhoea NCT03130114 · started 2017 · scored riskier than 36% of active trials completed
- Vitamin-D Supplementation: Impact on Severe Pneumonia Among Under-five Children NCT02185196 · started 2014 · scored riskier than 14% of active trials completed
- Defining Antibiotic Treatment Duration for Ventilator - Associated Lung Infection NCT03382548 · started 2018 · scored riskier than 32% of active trials completed
Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.